224 related articles for article (PubMed ID: 27460230)
1. [Selective internal radioembolization in nonresectable hepatocellular carcinoma].
Bauschke A; Altendorf-Hofmann A; Freesmeyer M; Winkens T; Malessa C; Schierz JH; Teichgraeber U; Settmacher U
Chirurg; 2016 Nov; 87(11):956-963. PubMed ID: 27460230
[TBL] [Abstract][Full Text] [Related]
2. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
3. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
6. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
7. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
8. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma.
Iñarrairaegui M; Pardo F; Bilbao JI; Rotellar F; Benito A; D'Avola D; Herrero JI; Rodriguez M; Martí P; Zozaya G; Dominguez I; Quiroga J; Sangro B
Eur J Surg Oncol; 2012 Jul; 38(7):594-601. PubMed ID: 22440743
[TBL] [Abstract][Full Text] [Related]
9. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
10. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
[TBL] [Abstract][Full Text] [Related]
12. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience.
Abdelfattah MR; Al-Sebayel M; Broering D; Alsuhaibani H
Transplant Proc; 2015 Mar; 47(2):408-11. PubMed ID: 25769582
[TBL] [Abstract][Full Text] [Related]
13. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization.
Delicque J; Hermida M; Piron L; Allimant C; Belgour A; Pageaux GP; Ben Bouallegue F; Assenat E; Mariano-Goulart D; Guiu B; Cassinotto C
Diagn Interv Imaging; 2019 Nov; 100(11):689-697. PubMed ID: 31281074
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
[TBL] [Abstract][Full Text] [Related]
15. [Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences].
Herber S; Pitton M; Mönch C; Schneider J; Manzl N; Kummer I; Kanzler S; Schuchmann M; Junginger T; Düber C; Otto G
Zentralbl Chir; 2007 Aug; 132(4):306-15. PubMed ID: 17724633
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
17. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
19. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
Shin BS; Park MH; Jeon GS
Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
